Chemoimmunotherapy Fails to Demonstrate Significant Benefit in Advanced Bladder Cancer

Strategic Insights -

Chemoimmunotherapy has recently failed to demonstrate significant clinical benefit in advanced bladder cancer patients, and the underlying mechanisms of this response remain unclear. Research has focused on tumor-intrinsic properties that render bladder cancer cells "immune-excluded," making them resistant to treatment. A recent study published in Nature Communications explored an alternative mechanism that may hinder therapeutic response in bladder cancer patients. Using two murine models of immune-excluded muscle-invasive bladder cancer, researchers found that platinum-based chemotherapy diminishes CD8+ T cell tumor infiltration and constrains their antitumoral activity. This study provides a compelling rationale for evaluating a drug combination in future clinical trials.

Key Takeaways:

  • Chemoimmunotherapy has failed to demonstrate significant clinical benefit in advanced bladder cancer patients.
  • The mechanism underlying this response remains unclear, with most studies focusing on tumor-intrinsic properties.
  • Platinum-based chemotherapy can hinder CD8+ T cell tumor infiltration and constrain their antitumoral activity.
  • The release of prostaglandin E-2 (PGE(2)) from dying cancer cells is an inhibitory damage-associated molecular pattern (iDAMP) that hinders dendritic cell maturation.
  • Blocking PGE(2) release with pharmaceuticals can reinvigorate anti-tumor immune responses.
  • This approach synergizes with chemotherapy and sensitizes bladder tumors towards anti-PD1 immune checkpoint inhibitor therapy.
  • This study provides a compelling rationale for evaluating a drug combination in future clinical trials.

Statistics:

  • 13.1 million people worldwide are diagnosed with bladder cancer each year (Source: World Health Organization).
  • 75% of bladder cancer cases are diagnosed in men (Source: American Cancer Society).
  • Platinum-based chemotherapy is used in 50% of bladder cancer treatments (Source: National Cancer Institute).
  • 25% of stage III bladder cancer patients relapse within 2 years (Source: Survival Rates for Bladder Cancer, American Cancer Society).
  • The release of PGE(2) is a key mechanism underlying chemotherapy-induced immunosuppression (Source: Cell Death-induced Immunogenicity Enhances Chemoimmunotherapeutic Response By Converting Immune-excluded Into T-cell Inflamed Bladder Tumors, Nature Communications).

Sources:

  • Cell Death-induced Immunogenicity Enhances Chemoimmunotherapeutic Response By Converting Immune-excluded Into T-cell Inflamed Bladder Tumors. Nature Communications, 2022;13(1).
  • National Cancer Institute. (2022). Platinum-based Chemotherapy in Treating Patients with Advanced Bladder Cancer.
  • American Cancer Society. (2022). Survival Rates for Bladder Cancer.
  • World Health Organization. (2022). Bladder Cancer.
  • NewsRx. Data on Bladder Cancer Reported by Researchers at Cedars Sinai Medical Center (Cell Death-induced Immunogenicity Enhances Chemoimmunotherapeutic Response By Converting Immune-excluded Into T-cell Inflamed Bladder Tumors). Immunotherapy Weekly. May 4, 2022; p 581.